


1/12

Fig. 1



2/12

Fig.
2B





Fig.
2A






Fig. 3

1 10 20 30 40 50 60
NSVHPCCDPVKCEPREGEHCISGPPCCRNCFYFLRAGTVCKRAVGDDVDDYCSGITPDCPRNRYKGED
|----- N-terminal sequencing -----
|----- K5 -----
|----- K3 ----- R K1b V - |
|----- K1a ----- N K2 I - |----- K4 -----
D D

Fig. 4A

1 10 20 30 40 50 60
NSVHPCCDPVKCEPREGEHCISGPPCCRNCKFLNAGTICKRAMLLDGLNDYCTGISTDCPRNRYKGED
T
|----- N-terminal sequencing -----
|----- CNBr-1 -----
|----- K1 -----
|----- T K7 ----- K6 ----- K10a -- T -----
|----- K4 ----- |----- K10b -- S -----

Fig. 4B

09/485323

<u>Eristostatin</u>	QEEPCATG	PCRRCK	FKRAGK	VRVA	<u>RGD</u>	WNDDYCT	GKSD	OPRNPWNG
<u>Echistatin</u>		ECESGP	CCRNCK	FLKEGT	ICKRA	<u>RGD</u>	DMDDYCN	GKTODOPRNP
<u>Flavoridin</u>								HKGPAT
<u>Kistrin</u>	GEEDCG	SPSNPC	DAATCK	LRPGAQ	CADGLCCD	QCRFKKKT	GIORIA	<u>RGD</u>
<u>EC3A</u>	GKECD	SSPENP	CCDDAT	CKLRPGAQ	CGEGLCC	CEQCKFSR	AGKIRIP	<u>RGD</u>
<u>EC3B</u>								MPDDRCTG
<u>Le3 (disintegrin domain)</u>								QSADOPRYH
	NSVHP	CCDPVK	CEPREGEH	CI	SGPCCRNCK	FLRAGT	VCKRA	<u>VGD</u>
								DVDDYCSG
	NSVHP	CCDPVK	CEPREGEH	CI	SGPCCRNCK	FLNAGT	ICKRA	<u>MLD</u>
								GLNDYCTG
	...NSGN	PCCDPVT	CQPRRGEH	CVSGKCC	CRNCK	FLRAGT	VCKRA	<u>VGD</u>
								DMDDYCTG
								ISSDOPRNP
								PYKD

Fig. 5

6/12




Fig. 6

7/12




Fig. 7

8/12

Fig. 8




Fig. 9B





Fig. 9A



10/12




Fig. 10

29/485323

11/12

Fig. 11B






Fig. 11A





125